Apimeds Pharmaceuticals US, Inc. APUS
2.83 USD -0.14 (-4.81%)
Nov 4, 2026, 10:20 AM EST
2.83 Day range 2.83
1.51 52-week range 59.70
- YTD
- -82.76%
- 1 year
- -89.68%
Financial health
Altman Z-Score
-2.09 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 5
Valuation
P/E -3.0×
FY 2021 5y median -3.0× FY 2025
P/S 0.0×
FY 2021 5y median 0.0× FY 2025
P/B 0.1×
FY 2021 5y median -1.9× FY 2025
P/FCF -2.0×
FY 2021 5y median -3.5× FY 2025
EV/EBITDA -4.2×
FY 2021 5y median -3.2× FY 2025
EV/Sales 0.0×
FY 2021 5y median 0.0× FY 2025
FCF Yield -50.3%
FY 2021 5y median -28.9% FY 2025
Profitability
Gross Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2021 5y median 0.0% FY 2025
ROE -3.9%
FY 2021 5y median 93.7% FY 2025
ROIC -7.4%
FY 2021 5y median -7.4% FY 2025
ROA -3.7%
FY 2021 5y median -596.1% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2021 FY 2025
Operating Income -834.2%
FY 2021 FY 2025
EPS (diluted) 50.0%
FY 2021 FY 2025
Free Cash Flow -1124.6%
FY 2021 FY 2025
Financial Health
Current Ratio 1.3×
FY 2021 5y median 1.3× FY 2025
Quick Ratio 1.3×
FY 2021 5y median 1.3× FY 2025
Debt / Equity 0.1×
FY 2021 5y median -0.4× FY 2025
Net Debt / EBITDA -1.1×
FY 2021 5y median -0.5× FY 2025
Interest Coverage -42.1×
FY 2021 5y median -21.9× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31